Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer

被引：0
|
作者：
Qiu, H. [1 ]
Dai, Y. [1 ]
Huang, T. [1 ]
Sun, L. [1 ]
Zhuang, L. [1 ]
Zhang, M. [1 ]
Zou, Y. [1 ]
Yuan, X. [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.949
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
428P
引用
收藏
页码：S548 / S548
页数：1
相关论文
共 50 条
  • [41] Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study
    Nakashima, Masayuki
    Ide, Kazuki
    Kawakami, Koji
    TARGETED ONCOLOGY, 2019, 14 (03) : 295 - 306
  • [42] Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study
    Masayuki Nakashima
    Kazuki Ide
    Koji Kawakami
    Targeted Oncology, 2019, 14 : 295 - 306
  • [43] A real-world multicentre retrospective study of low-dose apatinib for HER2-negative metastatic breast cancer
    Zeng, Tianyu
    Li, Wei
    Yin, Yongmei
    ANNALS OF ONCOLOGY, 2021, 32 : S319 - S319
  • [44] Cetuximab plus FOLFIRI for irinotecan-refractory metastatic colorectal cancer: A retrospective study
    Koo, Dong Hoe
    Lee, Jae-Lyun
    Kim, Tae Won
    Ryu, Min-Hee
    Chang, Heung Moon
    Lee, Sung Sook
    Kim, Min Kyoung
    Sym, Sun Jin
    Lee, Jung Shin
    Kang, Yoon-Koo
    ANNALS OF ONCOLOGY, 2006, 17 : 131 - 131
  • [45] Exploratory biomarker findings from regorafenib plus toripalimab in patients with refractory metastatic colorectal cancer (REGOTORI study)
    Yao, Y.
    Jin, Y.
    Wang, M.
    Hou, T.
    Chen, Y.
    He, M.
    Li, M.
    Huang, Y.
    Wang, Z.
    Lv, Z.
    Zou, X.
    Zhao, Q.
    Wang, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S310 - S310
  • [46] Efficacy, safety, and predictors of fruquintinib plus antiprogrammed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study
    Yang, Xiaolin
    Yin, Xianli
    Qu, Xiaozhou
    Guo, Geyang
    Zeng, Yidong
    Liu, Wu
    Jagielski, Mateusz
    Liu, Zhenyang
    Zhou, Huijun
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (06) : 2425 - 2435
  • [47] Docetexal plus S-1 Versus Oxaliplatin plus S-1 for First-Line Treatment of Patients with Advanced Gastric Cancer: A Retrospective Study
    Wang, Mei
    Wu, Meihong
    Wang, Wei
    Wang, Qingshui
    Wang, Yajie
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 (1-2) : 24 - 28
  • [48] Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
    Conti, Matteo
    Bolzacchini, Elena
    Luchena, Giovanna
    Bertu', Lorenza
    Tagliabue, Paola
    Aglione, Stefania
    Ardizzoia, Antonio
    Arnoffi, Jessica
    Guida, Francesco Maria
    Bertolini, Alessandro
    Pastorini, Alessandro
    Duro, Maria
    Bettega, Donato
    Roda', Giovambattista
    Artale, Salvatore
    Squizzato, Alessandro
    Giordano, Monica
    CANCERS, 2023, 15 (13)
  • [49] Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study
    Jiang, Feng-E
    Zhang, Hui-Juan
    Yu, Cai-Yan
    Liu, Ai-Na
    NEOPLASMA, 2021, 68 (04) : 861 - 866
  • [50] Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study
    Chen, Can
    Luo, Xi
    Tang, Wenhua
    Geng, Haofei
    Martinez-Perez, Julia
    Price, Timothy
    Kang, Lili
    Lu, Honglian
    Zhang, Yanling
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04) : 1497 - 1507
12345